Effect of a patient-tailored integrative medicine program on gastro-intestinal concerns and quality of life in patients with breast and gynecologic cancer.

Autor: Shalom-Sharabi I; Integrative Oncology Program, The Oncology Service and Lin Medical center, Clalit Health Services, Haifa and Western Galilee District, 35 Rothschild St., Haifa, Israel., Samuels N; Integrative Oncology Program, The Oncology Service and Lin Medical center, Clalit Health Services, Haifa and Western Galilee District, 35 Rothschild St., Haifa, Israel.; Tal Center for Integrative Oncology, Sheba Medical Center, Institute of Oncology, Tel Hashomer, Israel., Lavie O; Department of Obstetrics and Gynecology, Gynecologic Oncology Service, Carmel Medical Center, Haifa, Israel., Lev E; Department of Eretz Israel Studies, University of Haifa, Haifa, Israel., Keinan-Boker L; Faculty of Social Welfare and Health Sciences, School of Public Health, University of Haifa, Haifa, Israel.; Israel Center for Disease Control, Israel Ministry of Health, Haifa, Israel., Schiff E; Department of Internal Medicine, and the Integrative Medicine Service, Bnai-Zion Hospital, Haifa, Israel., Ben-Arye E; Integrative Oncology Program, The Oncology Service and Lin Medical center, Clalit Health Services, Haifa and Western Galilee District, 35 Rothschild St., Haifa, Israel. eranben@netvision.net.il.; Complementary and Traditional Medicine Unit, Department of Family Medicine, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. eranben@netvision.net.il.; Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel. eranben@netvision.net.il.
Jazyk: angličtina
Zdroj: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2017 Jul; Vol. 143 (7), pp. 1243-1254. Date of Electronic Publication: 2017 Feb 28.
DOI: 10.1007/s00432-017-2368-8
Abstrakt: Context and Objectives: This study was conducted to assess the impact of a patient-tailored complementary/integrative medicine (CIM) program on gastro-intestinal (GI) symptoms and other concerns in female patients with breast/gynecological cancer undergoing chemotherapy.
Methods: Patients with breast/gynecological cancer reporting GI-related concerns were referred to an integrative physician (IP) consultation. The treatment group included patients agreeing to attend the consultation; controls those who did not. The Edmonton Symptom Assessment Scale (ESAS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were administered at baseline and at 6 weeks. Adherence to integrative care (AIC) was defined as attending ≥4 CIM treatments, with ≤30 days between each session.
Results: Of 496 patients approached, 289 reported GI-related concerns. Optimal assessment at baseline and 6 weeks was achieved in 117 patients in the treatment arm, with 86 adhering to the CIM program (AIC subgroup); and in 89 of controls. EORTC scores improved more significantly in the treatment arm for appetite (P = 0.018), fatigue (P = 0.026), cognitive functioning (P < 0.001) and emotional functioning (P = 0.002); and ESAS scores for pain (P = 0.038), anxiety (P = 0.016), and sleep (P = 0.001). EORTC scores improved more significantly in the AIC group for global health status/QOL (P = 0.041), physical functioning (P = 0.004), role functioning (P = 0.011), appetite (P = 0.019), and fatigue (P = 0.001); and ESAS scores for pain (P = 0.048), fatigue (P = 0.011), drowsiness (P = 0.035), and appetite (P = 0.002).
Conclusion: The integration of CIM may improve chemotherapy-related GI and other QOL-related concerns in patients with breast and gynecological cancer, with greater benefit observed in adherent patients.
Databáze: MEDLINE
Externí odkaz: